Tempus AI is a leader in applying AI solutions to cancer diagnosis. The company announced a new platform for speeding up the ...

AstraZeneca, Tempus and Pathos will develop an AI-driven foundational model to develop therapeutics in oncology.

Tempus AI has signed a three-way deal with AstraZeneca and Pathos AI to construct a data-based oncology model that could ...

Tempus AI has announced that it is using the TIME Network for Phase I trials to expedite site activation and enrolment.

"Tempus is proud to showcase a comprehensive collection of scientific research this year, highlighting the impact of our ...

“Tempus is proud to showcase a comprehensive collection of scientific research this year, highlighting the impact of our multimodal dataset and AI-enabled diagnostic solutions on cancer research ...

CHICAGO - Tempus AI, Inc. (NASDAQ: TEM), a leader in AI-driven precision medicine with a market capitalization of $9.15 billion, announced the launch of Tempus Loop, a new platform designed to ...

Tempus AI has reported impressive growth, but some of the volatile quarterly numbers have chased off aggressive investors. See why TEM stock is a Buy.

"Cancer drug discovery and clinical development ... CAZ's chief AI and data scientist for oncology R&D. The alliance with Tempus and Pathos AI "will accelerate and increase the probability of ...

Tempus stands to earn $200 million in data licensing and model development fees from the collaborations, the release said.